Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

Impact · against what's priced in

Kura Oncology is expanding the strategic scope of its KO-7246 menin inhibitor into diabetes. This diversification of the drug's potential application provides a positive catalysts for the pipeline beyond its primary oncology targets.

Scored by the NIS engine · methodology.

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

biotech
healthcare
KURA
clinical data

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

How each ticker is affected

BBNX DEADLINE NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

How each ticker is affected

BBNX DEADLINE NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Track these names every morning.

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

TRexBio Announces Closing of Initial Public Offering

BMY Reports Mixed Phase III Trial Results, Stock Down

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

How each ticker is affected

Next reads from the same story arc

BBNX DEADLINE NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

How each ticker is affected

Next reads from the same story arc

BBNX DEADLINE NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Track these names every morning.

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

TRexBio Announces Closing of Initial Public Offering

BMY Reports Mixed Phase III Trial Results, Stock Down